Recursion Pharmaceuticals Faces Cash Burn and Pipeline Uncertainty Amid Partnership Milestones
Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) has turned its AI‑driven discovery engine into a double‑edged sword: w...
Read story →Tag: Pharmaceuticals
View all →
Corvus Pharmaceuticals Advances Soquelitinib to Phase 3 for Peripheral T-Cell Lymphoma While Expanding Atopic Dermatitis Trial
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) announced on October 10 2024 that it has launched a registrational Phase 3 st...
Read story →
Eton Pharmaceuticals Accelerates Rare-Disease Portfolio with Increlex and Amglidia Acquisitions, Eyes 16-Product Line
Eton Pharmaceuticals (NASDAQ: ETON) announced that it has closed two acquisitions this quarter, adding the Increlex and ...
Read story →
Johnson & Johnsons Q4 2024 Earnings Boost Stock, Highlights Resilient Portfolio
Johnson & Johnson’s fourth‑quarter 2024 earnings release sent the company’s shares soaring 22 percent in the first...
Read story →
Ionis Pharmaceuticals Faces Dual Trial Setbacks Amid Strong Core Asset Base
When Ionis Pharmaceuticals Inc. (NASDAQ: IONS) announced that two of its flagship programs had failed to hit primary end...
Read story →
Al Majed for Oud Pursues Regional Expansion with Planned Acquisition of Al Safa Pharmaceuticals
On 13 June, Riyadh‑based Al Majed for Oud announced a non‑binding agreement to acquire Al Safa Pharmaceuticals and M...
Read story →
Syndax Pharmaceuticals Holds 2026 Annual Shareholder Meeting Amid Strong Oncology Pipeline and Recent Financial Growth
On June 10, 2026, Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) convened its annual meeting of stockholders through a recor...
Read story →